EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis

Florence Schleich, Stelios Loukides iD, Rekha Chaudhuri, Joerg D Leuppi, Enrico Heffler, Cristian Domingo, Claudio Micheletto, Thomas Paulsson, Nina Gaw, Konstantina Kallinikou, Carla Vossen, Florent Guelfucci und 3 weitere

Allergy · 2025

DOI: 10.1111/all.16618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Florence Schleich und 14 weiteren Autor:innen. Beteiligte Einrichtung: GIGA I3, Respiratory Medicine, Exercise Physiology Laboratory, University of Liège, Liège, Belgium. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Nasal Polyps, Sinusitis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK-sponsored study 219821.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe asthma with an eosinophilic phenotype (SAEP) and chronic rhinosinusitis with nasal polyps (CRSwNP) are predominantly type 2‐driven diseases, characterised by eosinophilic inflammation and substantial disease burden. Mepolizumab, a humanised monoclonal antibody that targets interleukin‐5, a key cytokine in type 2 inflammation, is an effective, approved treatment both in SAEP and CRSwNP. We aimed to analyse real‐world evidence of mepolizumab effectiveness in patients with comorbid SAEP and CRSwNP.

Methods

This study pooled five existing, predominantly European cohorts to describe the impact of mepolizumab on the rate of clinically significant exacerbations (CSEs) and other outcomes in adults with SAEP without and with comorbid CRSwNP (SAEP[−]CRSwNP and SAEP[+]CRSwNP, respectively).

Results

Overall, 1037 patients were included. Baseline characteristics were similar in both cohorts. Mepolizumab was associated with a reduction from baseline in the annual rate of CSEs at 12‐months post‐initiation (SAEP[−]CRSwNP: 72.7%; SAEP[+]CRSwNP: 79.7%), irrespective of baseline blood eosinophil count (BEC). When patients with SAEP[+]CRSwNP were compared with patients with SAEP[−]CRSwNP, a 30.0% incremental benefit in the reduction of CSEs was observed. At 12‐months post‐initiation, mepolizumab was also associated with a reduction in oral corticosteroid use and BEC, and an improvement in lung function and Asthma Control Test (ACT) scores in both cohorts. Post‐mepolizumab initiation, ≥ 3 clinical remission criteria were fulfilled by 47.2% and 52.3% of patients with SAEP[−]CRSwNP and SAEP[+]CRSwNP, respectively.

Conclusions

The results provide a greater understanding of mepolizumab's effectiveness, demonstrating a substantial improvement in asthma outcomes, irrespective of baseline BEC and the presence of comorbid CRSwNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaNasal PolypsSinusitisRhinitisAnti-Asthmatic AgentsHumansMaleFemaleChronic DiseaseMiddle AgedTreatment OutcomeAdultSeverity of Illness IndexAgedEosinophilsRhinosinusitis

Stichwörter der Autor:innen

asthmabiologics

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • GIGA I3, Respiratory Medicine, Exercise Physiology Laboratory, University of Liège, Liège, Belgium.
  • 2nd Respiratory Medicine Department Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • University of Glasgow, Glasgow, Scotland, UK.
  • Cantonal Hospital Baselland, Liestal and Medical Faculty, University of Basel, Basel, Switzerland.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

ORCID-Profile: Stelios Loukides, Ines Palomares

Förderung

  • GSK-sponsored study 219821

Zitieren

APA

Schleich, F., Loukides, S., Chaudhuri, R., Leuppi, J. D., Heffler, E., Domingo, C., Micheletto, C., Paulsson, T., Gaw, N., Kallinikou, K., Vossen, C., Guelfucci, F., Menon, J., Ngami, A., & Palomares, I. (2025). Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis. Allergy. https://doi.org/10.1111/all.16618

Vancouver

Schleich F, Loukides S, Chaudhuri R, Leuppi JD, Heffler E, Domingo C, et al. Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis. Allergy. 2025. doi:10.1111/all.16618

BibTeX
@article{Schleich2025,
  author = {Schleich, Florence and Loukides, Stelios and Chaudhuri, Rekha and Leuppi, Joerg D and Heffler, Enrico and Domingo, Cristian and Micheletto, Claudio and Paulsson, Thomas and Gaw, Nina and Kallinikou, Konstantina and Vossen, Carla and Guelfucci, Florent and Menon, Jyothi and Ngami, Armel and Palomares, Ines},
  title = {Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16618}
}
Kostenlos starten →